Primary:
•The PNH Registry will collect data to evaluate safety data specific to the use of Soliris
•The PNH Registry will collect data to characterize the progression of PNH as well as clinical outcomes, mortality and morbidity in Soliris and non-Soliris treated patients

Secondary:
•Facilitates sub-studies in Soliris treated PNH patients that were requested by regulatory authorities such as: Immunogenicity evaluation [Human Anti-Human Antibodies (HAHA) sub-study] and Thromboprophylaxis withdrawal study (Parasol study)
•Raising PNH awareness in the medical community and subject/potential subject population.